U.S. Secures 500,000 More Doses of AstraZeneca’s COVID-19 Antibody Combo
The U.S. government has ordered 500,000 more doses of AstraZeneca’s experimental long-acting antibody combination for preventing and treating COVID-19.
Valued at $205 million, the new order builds on a previous $486 million deal forged in October for development assistance and an initial 100,000 doses of the therapy, with the Department of Defense having also negotiated a separate agreement for 100,000 doses. This bring the government’s total potential supply of AZD7442 to 700,000 doses, set for distribution in 2021 pending regulatory approval.
AZD7442 is being evaluated in five ongoing phase 3 trials enrolling more than 9,000 participants worldwide.